Which kinase does brigatinib primarily target?

The core target of Brigatinib (Brigatinib) is the anaplastic lymphoma kinase (ALK) kinase. ALKKinase plays an important role in regulating cell growth and differentiation in cells. When the ALK gene is rearranged, the ALK kinase becomes extremely active, thereby driving the continued proliferation of cancer cells and the formation of tumors. Especially in ALK-positive non-small cell lung cancer, rearrangement of the ALK gene is often the key to tumor development. Brigatinib specifically inhibits the activity of ALK kinase, effectively blocking its promotion of cell proliferation, thereby inhibiting tumor growth.

It is worth mentioning that brigatinib (Brigatinib) not only has a significant inhibitory effect on wild-type ALK kinase, but can also effectively deal with a variety of ALK mutants. ALK Different mutations in the gene can lead to changes in the kinase structure, which may affect the binding of drugs to the kinase and the inhibitory effect. The design of Brigatinib fully considers the existence of these mutants, making it effective against L1196M, G12 Common ALK mutants including 69A, S1206Y etc. This broad spectrum of inhibitory effects makes brigatinib significantly advantageous in dealing with drug resistance and complex tumor biology.

Compared with the first-generation ALKinhibitor crizotinib (Crizotinib), brigatinib has demonstrated greater efficacy in inhibiting ALKkinase. Although crizotinib is effective in some ALK-positive patients, many patients develop resistance to crizotinib over time. And Brigatinib (Brigatinib)by targeting the different binding sites and mechanisms of ALKkinase, it has overcome some of the resistance mutations of crizotinib, thus showing a more durable therapeutic effect.

In addition,Brigatinib also has certain inhibitory effects on some other kinases, such asROS1 and EGFR etc. This multi-target inhibitory ability makes brigatinib more flexible in the treatment of complex and variable tumor conditions and can respond to different pathological characteristics.